drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous, gene-modified T cells transduced with a lentiviral vector to express a CD19-specific chimeric antigen receptor (CAR), enabling antigen-specific activation and cytotoxic killing of CD19-positive B-lineage cells; administered after lymphodepleting chemotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express a CD19-specific chimeric antigen receptor that recognizes CD19 on B-lineage cells, triggering CAR signaling to activate, expand, and mediate cytotoxic killing of CD19-positive malignant and normal B cells after lymphodepleting chemotherapy.
drug_name
UCD19 (CD19-directed CAR T cells)
nct_id_drug_ref
NCT05535855